Results 161 to 170 of about 3,510,452 (319)

How long does it take to complete and publish a systematic review of animal studies? [PDF]

BMC Med Res Methodol
Bugajska JV, Hild BF, Brüschweiler D, Meier ED, Bannach-Brown A, Wever KE, Ineichen BV.   +6 more
europepmc   +1 more source

Unifying two medicines to fight pain and to make anesthesia safer

Frontiers in Veterinary Science, 2023
Karine Portier, Karine Portier
doaj   +1 more source

EGFR‐STAT3 activation provides a therapeutic rationale for targeting aggressive ETV1‐positive prostate cancer

Molecular Oncology, EarlyView.
Cotargeting EGFR and STAT3 with Erlotinib and TTI‐101 impairs both 2D and 3D growth of ETV1‐overexpressing prostate cancer cells by disrupting a self‐sustaining ETV1–EGFR positive feedback loop that promotes EGFR and STAT3 expression and phosphorylation (activation).
Elsa Gomes Paiva, Bernardo Orr, Ana Azeredo, Andreia Brandão, Manuel R. Teixeira, Paula Paulo   +5 more
wiley   +1 more source

Nurturing care group approach for improving animal faeces management in Ghana. [PDF]

Sci Rep
Dwumfour-Asare B, Appiah-Effah E, Nyarko KB, Tidwell JB.   +3 more
europepmc   +1 more source

Remarks on Plague in the Lower Animals [PDF]

, 1900
F. G. Clemow
openalex   +1 more source

Cytomegalovirus infection is common in prostate cancer and antiviral therapies inhibit progression in disease models

Molecular Oncology, EarlyView.
Human cytomegalovirus infection is common in normal prostate epithelium, prostate tumor tissue, and prostate cancer cell lines. CMV promotes cell survival, proliferation, and androgen receptor signaling. Anti‐CMV pharmaceutical compounds in clinical use inhibited cell expansion in prostate cancer models in vitro and in vivo, motivating investigation ...
Johanna Classon, Moa Stenudd, Margherita Zamboni, Kanar Alkass, Carl‐Johan Eriksson, Lars Pedersen, Alrik Schörling, Anna Thoss, Anders Bergh, Pernilla Wikström, Hans‐Olov Adami, Henrik Toft Sørensen, Henrik Druid, Jonas Frisén   +13 more
wiley   +1 more source

PKSmart: an open-source computational model to predict intravenous pharmacokinetics of small molecules. [PDF]

J Cheminform
Seal S, Trapotsi MA, Mahale M, Subramanian V, Greene N, Spjuth O, Bender A.   +6 more
europepmc   +1 more source

ON THE PROTEOLYTIC ENZYMES OF ANIMAL TISSUES

, 1948
Helmut R. Gutmann, Joseph S. Fruton
openalex   +1 more source

XXVII.—On the Calcispongiæ, their position in the animal kingdom, and their relation to the theory of descendence [PDF]

, 1873
Ernst Häckel
openalex   +1 more source

Integrative miRNOMe profiling reveals the miR‐195‐5p–CHEK1 axis and its impact on luminal breast cancer outcomes

Molecular Oncology, EarlyView.
In luminal (ER+) breast carcinoma (BC), miRNA profiling identified miR‐195‐5p as a key regulator of proliferation that targets CHEK1, CDC25A, and CCNE1. High CHEK1 expression correlates with worse relapse‐free survival after chemotherapy, especially in patients with luminal A subtype.
Veronika Boušková, Marie Ehrlichová, Alžběta Spálenková, Ivona Krus, Simona Šůsová, Viktor Hlaváč, Vlasta Němcová, Renata Koževnikovová, Markéta Trnková, David Vrána, Jiří Gatěk, Kateřina Kopečková, Marcela Mrhalová, Soňa Měšťáková, Pavel Souček   +14 more
wiley   +1 more source